Objective To investigate the early diagnostic value of serum neuron‐specific enolase(NSE) in neonaal hypoxic‐is‐chemic encephalopathy(HIE) .Methods Eighty full term neonates with HIE in the neonatology department of our hospital from January 2013 to June 2014 were selected as the observation group and contemporaneous 30 full term neonates without perinatal as‐phyxia as the control group .Serum NSE was detected within 24 h after birth and after 2‐week comprehensive treatment(mainly in‐cluding 10 d ganglioside therapy) .The neonatal patients were divided into the mild HIE in 18 cases ,moderate HIE in 48 cases and severe HIE 14 cases according to the HIE severity .The control group was performed the serum NSE detection within postnatal 24 h .Results The serum NSE level in the mild ,moderate and severe HIE groups was significantly higher than that in the control group(P<0 .05) .The re‐detected results of serum NSE after 2‐week comprehensive treatment in the mild ,moderate and severe HIE groups were significantly decreased when compared with those at admission ,the differences were statistically significant(P<0 .05) .Conclusion Serum NSE is a sensitive biochemical indicator for early diagnosing neonatal HIE ,and also reflect the severity of neonatal HIE .

Peptides are a particular molecule class with inherent attributes of some small-molecule drugs and macromolecular biologics, thereby inspiring continuous searches for peptides with therapeutic and/or agrochemical potentials. However, the success rate is decreasing, presumably because many interesting but less-abundant peptides are so scarce or labile that they are likely 'overlooked' during the characterization effort. Here, we present the biochemical characterization and druggability improvement of an unprecedented minor fungal RiPP (ribosomally synthesized and post-translationally modified peptide), named acalitide, by taking the relevant advantages of metabolomics approach and disulfide-bridged substructure which is more frequently imprinted in the marketed peptide drug molecules. Acalitide is biosynthetically unique in the macrotricyclization via two disulfide bridges and a protease (AcaB)-catalyzed lactamization of AcaA, an unprecedented precursor peptide. Such a biosynthetic logic was successfully re-edited for its sample supply renewal to facilitate the identification of the in vitro and in vivo antiparkinsonian efficacy of acalitide which was further confirmed safe and rendered brain-targetable by the liposome encapsulation strategy. Taken together, the work updates the mining strategy and biosynthetic complexity of RiPPs to unravel an antiparkinsonian drug candidate valuable for combating Parkinson's disease that is globally prevailing in an alarming manner.